Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension

Pediatric Pulmonology

Volumn 48, Issue 1, 2013, Pages 27-34

  Takatsuki, Shinichi ^a   Rosenzweig, Erika B ^b   Zuckerman, Warren ^b   Brady, Daniela ^b   Calderbank, Michelle ^a   Ivy, D Dunbar ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

endothelin receptor antagonists; safety; tolerability; World Health Organization

Indexed keywords

AMBRISENTAN; BOSENTAN;

ADD ON THERAPY; ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTERY SURGERY; ARTICLE; BLALOCK HANLON OPERATION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; FLUSHING; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; LIVER DYSFUNCTION; LUNG ARTERY PRESSURE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; MYALGIA; NOSE OBSTRUCTION; OPEN STUDY; PERIPHERAL EDEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; WORLD HEALTH ORGANIZATION;

EID: 84872866508     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22555     Document Type: Article

References (21)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T,. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ,. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
3. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ,. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 62S-67S.
4. Galie N, Manes A, Branzi A,. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237.
5. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M,. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994; 23: 1427-1433.
6. Okada M, Yamashita C, Okada K,. Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation 1995; 92: 114-119.
7. Kingman M, Ruggiero R, Torres F,. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2009; 10: 1847-1858.
8. Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB,. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011; 107: 1381-1385.
9. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ,. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139: 109-114.
10. Blalock SE, Matulevicius S, Mitchell LC, Reimold S, Warner J, Peshock R, Torres F, Chin KM,. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 2010; 16: 121-127.
11. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ,. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
12. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G,. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
13. Opitz CF, Ewert R, Kirch W, Pittrow D,. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter ? Eur Heart J 2008; 29: 1936-1948.
14. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ,. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.
15. Burgess G, Hoogkamer H, Collings L, Dingemanse J,. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64: 43-50.
16. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI,. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008; 48: 610-618.
17. Spence R, Mandagere A, Dufton C, Venitz J,. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol 2008; 48: 1451-1459.
18. Dingemanse J, van Giersbergen PL,. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089-1115.
19. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, Ivy DD, Jais X, Schulze-Neick I, Galie N, Morganti A, Dingemanse J, Kusic-Pajic A, Berger RM,. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948-955.
20. Rubin LJ, Dufton C, Gerber MJ,. Ambrisentan for pulmonary arterial hypertension. Future Cardiol 2005; 1: 425-432.
21. Walker G, Mandagere A, Dufton C, Venitz J,. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol 2009; 67: 527-534.